References
- http://www.nhlbi.nih.gov/guidelines/asthma/asthupdt.htm National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. 2007. Available at. Accessed August 29, 2007
- Global Initiative for Asthma (GINA), http://www.ginasthma.com/Guidelineitem.asp??l1=2&l2=1&intId=60 Global strategy for asthma management and prevention, revised 2006. National Heart, Lung, and Blood Institute. Available at. Accessed December 6, 2006
- US Food and Drug Administration. Serevent Diskus, Advair Diskus, and Foradil Information (Long Acting Beta Agonists). U.S. Department of Health and Human Services, http://www.fda.gov/cder/drug/infopage/LABA/default.htm Available at. Accessed December 4, 2006
- Nelson H S, Weiss S T, Bleecker E R, Yancey S W, Dorinsky P M. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129: 15–26
- Smith C L, Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneim-Forsch 1998; 48: 956–960
- Stellato C, Atsuta J, Bickel C A, Schleimer R P. An in vitro comparison of commonly used topical glucocorticoid preparations. J Allergy Clin Immunol 1999; 104: 623–629
- Bernstein D I, Berkowitz R B, Chervinsky P, Dvorin D J, Finn A F, Gross G N, Karetzky M, Kemp J P, Laforce C, Lumry W, Mendelson L M, Nelson H, Pearlman D, Rachelefsky G, Ratner P, Repsher L, Segal A T, Selner J C, Settipane G A, Wanderer A, Cuss F M, Nolop K B, Harrison J E. Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler. Respir Med 1999; 93: 603–612
- Fish J E, Karpel J P, Craig T J, Bensch G W, Noonan M, Webb D R, Silverman B, Schenkel E J, Rooklin A R, Ramsdell J W, Nathan R, Leflein J G, Grossman J, Graft D F, Gower R G, Garay S M, Frigas E, Degraff A C, Bronsky E A, Bernstein D I, Berger W, Shneyer L, Nolop K B, Harrison J E. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. J Allergy Clin Immunol 2000; 106: 852–860
- Wardlaw A, Larivee P, Eller J, Cockcroft D W, Ghaly L, Harris A G. Efficacy and safety of mometasone furoate dry powder inhaler vs fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionate. Ann Allergy Asthma Immunol 2004; 93: 49–55
- O'Connor B, Bonnaud G, Haahtela T, Luna J M, Querfurt H, Wegener T, Lutsky B N. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. Ann Allergy Asthma Immunol 2001; 86: 397–404
- Piaggio G, Elbourne D R, Altman D G, Pocock S J, Evans S J. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006; 295: 1152–1160
- Adams N P, Bestall J C, Lasserson T J, Jones P W, Cates C. Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database Syst Rev 2005, CD003135
- Bousquet J, D'Urzo A, Hebert J, Barraza C H, Boulet L P, Suarez-Chacon R, Harnest U, Lundback B, Martinez Morales G, Nieminen M M, Nolop K B, Visser S, Lutsky B N. Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler. Eur Respir J 2000; 16: 808–816
- Nathan R A, Nayak A S, Graft D F, Lawrence M, Picone F J, Ahmed T, Wolfe J, Vanderwalker M L, Nolop K B, Harrison J E. Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate. Ann Allergy Asthma Immunol 2001; 86: 203–210
- Asmanex Twisthaler (mometasone furoate inhalation powder). Full Prescribing Information. Schering Corporation, Kenilworth, NJ 2005
- Hebert J, Kunkel G, Neffen H, Laitinen L, Peiffer G, Westbroek J, Tonnell A-B, Lutsky B. The safety and efficacy of mometasone furoate (MF) administered by dry powder inhaler (DPI) in patients previously maintained on high doses of prescribed inhaled corticosteroids (ICS) [abstract]. J Allergy Clin Immunol 2000; 105: S12
- Affrime M B, Kosoglou T, Thonoor C M, Flannery B E, Herron J M. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. Chest 2000; 118: 1538–1546
- Casale T B, Nelson H S, Stricker W E, Raff H, Newman K B. Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients. Ann Allergy Asthma Immunol 2001; 87: 379–385
- Fardon T C, Lee D K, Haggart K, McFarlane L C, Lipworth B J. Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Am J Respir Crit Care Med 2004; 170: 960–966